TABLE 1.
Resistance to D614G, BQ.1/BQ.1.1 and XBB/XBB.1/XBB.1.5 by different monoclonal antibodies.
|
Pseudovirus IC50 (ng/mL) |
Sotrovimab | Bebtelovimab | Imdevimab | Casirivimab | Cilgavimab | Tixagevimab | SA55 | SA58 | SA55 + SA58 |
Imdevimab + Casirivimab |
Cilgavimab + Tixagevimab |
Reference |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D614G | 23‐74 | 0.7‐2 | 2.1‐5.7 | 1.7‐5.6 | 2.5‐7 | 1.3‐2 | 11 | 0.9‐2 | 2.1 | 1.6‐5 | 1.3‐3 | 3, 41, 46 |
| BA.2 | 833‐918a | 0.9‐4.5 | 112‐590 | >10,000 | 6.1‐9 | 1,924‐4,312 | 7.2 | 5.1‐14 | 7.8 | 821‐1,985 | 8.2‐24.7 | 3, 36,41 46 |
| >10,000b | ||||||||||||
| BA.4/5 | 514‐1,088 | 0.8‐2 | 208‐520 | >10,000 | 11‐23 | >10,000 | 5 | 3.9‐9 | 4.5 | 700‐709 | 35‐40 | 3, 36, 41, 46 |
| BQ.1 | 600‐1,709 | >10,000# | >10,000 | >10,000 | >10,000 | >10,000 | 6.6 | 34‐44 | 9.2 | >10,000 | >10,000 | 3, 36 |
| 1,905* | ||||||||||||
| BQ.1.1 | 2,140‐7,640 | >10,000 | >10,000 | >10,000 | >10,000 | >10,000 | 5.9 | >10,000# | 10 | >10,000 | >10,000 | 3, 36, 41 |
| 900* | ||||||||||||
| XBB | 343‐963 | >10,000 | >10,000 | >10,000 | >10,000 | >10,000 | 5.3 | >10,000# | 9.8 | >10,000 | >10,000 | 3, 36 |
| 8,805* | ||||||||||||
| XBB.1 | 405‐896 | >10,000 | – | – | >10,000 | >10,000 | 6.2 | >10,000 | 12 | – | >10,000 | 3, 19 |
| XBB.1.5 | 915 | >10,000 | – | – | – | – | 7.1 | >10,000 | 11 | – | >10,000 | 19 |
arepresents ref. 3, ref. 36 and ref. 46; brepresents ref. 41; #represents ref. 3; *represents ref. 36.